EUVIMEDEUVIMED entdecken
Crossref

Vicinal diaryl pyrazole with tetrazole/urea scaffolds as selective angiotensin converting enzyme‐1/cyclooxygenase‐2 inhibitors: Design, synthesis, anti‐hypertensive, anti‐fibrotic, and anti‐inflammatory

Wael A A Fadaly, Yaseen A M M Elshaier, Fares E M Ali iD, Ali H El-Bahrawy, Khaled R A Abdellatif, Mohamed T M Nemr iD

Drug Development Research · 2024-06 · 85 (4)

DOI: 10.1002/ddr.22217 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 06.06.2024. Verfasst von Wael A A Fadaly und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt. Hauptthemen laut MEDLINE: Pyrazoles, Antihypertensive Agents, Angiotensin-Converting Enzyme Inhibitors, Tetrazoles. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 65 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As a hybrid weapon, two novel series of pyrazoles, 16a‐f and 17a‐f , targeting both COX‐2 and ACE‐1‐ N ‐domain, were created and their anti‐inflammatory, anti‐hypertensive, and anti‐fibrotic properties were evaluated. In vitro , 17b and 17f showed COX‐2 selectivity (SI = 534.22 and 491.90, respectively) compared to celecoxib (SI = 326.66) and NF‐κB (IC 50 1.87 and 2.03 μM, respectively). 17b (IC 50 0.078 μM) and 17 f (IC 50 0.094 μM) inhibited ACE‐1 comparable to perindopril (PER) (IC 50 0.048 μM). In vivo , 17b decreased systolic blood pressure by 18.6%, 17b and 17f increased serum NO levels by 345.8%, and 183.2%, respectively, increased eNOS expression by 0.97 and 0.52 folds, respectively and reduced NF‐κB‐p65 and P38‐MAPK expression by −0.62, −0.22, −0.53, and −0.24 folds, respectively compared to l ‐NAME (−0.34, −0.45 folds decline in NF‐κB‐p65 and P38‐MAPK , respectively). 17b reduced ANG‐II expression which significantly reversed the cardiac histological changes induced by L‐NAME.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazolesAntihypertensive AgentsAngiotensin-Converting Enzyme InhibitorsTetrazolesAnti-Inflammatory AgentsCyclooxygenase 2 InhibitorsAnimalsRatsDrug DesignMaleAntifibrotic AgentsCyclooxygenase 2Blood PressureHumansPeptidyl-Dipeptidase A

Stichwörter der Autor:innen

angiotensin‐II AT‐1 receptor blockers (ARBs)anti‐fibroticanti‐hypertensiveanti‐inflammatoryselective N‐domain‐angiotensin‐1‐converting enzyme (ACE‐1) inhibitorselective cyclooxygenase‐2 (COX‐2) inhibitor

Substanzen

PyrazolesAntihypertensive AgentsAngiotensin-Converting Enzyme InhibitorsTetrazolesAnti-Inflammatory AgentsCyclooxygenase 2 InhibitorsAntifibrotic AgentsCyclooxygenase 2Peptidyl-Dipeptidase A

Autor:innen und Institutionen

  • Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
  • Organic & Medicinal Chemistry Department, Faculty of Pharmacy, University of Sadat City, Menoufia, Egypt.
  • Department of Pharmacology & Toxicology, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Assiut, Egypt.
  • Department of Clinical Pharmacy, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Assiut, Egypt.
  • Pharmaceutical Sciences Department, Ibn Sina National College for Medical Studies, Jeddah, Kingdom of Saudi Arabia.
  • Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.

ORCID-Profile: Fares E M Ali, Mohamed T M Nemr

Zitieren

APA

Fadaly, W. A. A., Elshaier, Y. A. M. M., Ali, F. E. M., El-Bahrawy, A. H., Abdellatif, K. R. A., & Nemr, M. T. M. (2024). Vicinal diaryl pyrazole with tetrazole/urea scaffolds as selective angiotensin converting enzyme‐1/cyclooxygenase‐2 inhibitors: Design, synthesis, anti‐hypertensive, anti‐fibrotic, and anti‐inflammatory. Drug Development Research, 85(4). https://doi.org/10.1002/ddr.22217

Vancouver

Fadaly WAA, Elshaier YAMM, Ali FEM, El-Bahrawy AH, Abdellatif KRA, Nemr MTM. Vicinal diaryl pyrazole with tetrazole/urea scaffolds as selective angiotensin converting enzyme‐1/cyclooxygenase‐2 inhibitors: Design, synthesis, anti‐hypertensive, anti‐fibrotic, and anti‐inflammatory. Drug Development Research. 2024;85(4). doi:10.1002/ddr.22217

BibTeX
@article{Fadaly2024,
  author = {Fadaly, Wael A A and Elshaier, Yaseen A M M and Ali, Fares E M and El-Bahrawy, Ali H and Abdellatif, Khaled R A and Nemr, Mohamed T M},
  title = {Vicinal diaryl pyrazole with tetrazole/urea scaffolds as selective angiotensin converting enzyme‐1/cyclooxygenase‐2 inhibitors: Design, synthesis, anti‐hypertensive, anti‐fibrotic, and anti‐inflammatory},
  journal = {Drug Development Research},
  year = {2024},
  volume = {85},
  number = {4},
  doi = {10.1002/ddr.22217}
}
Kostenlos starten →